Mark Clemons profile picture

Contact Information

Mark Clemons, MD, FRCP (UK)
70170
mclemons@toh.on.ca

Division of Medical Oncology
The Ottawa Hospital Cancer Centre (Box 912)
501 Smyth Road
Ottawa ON
K1H 8L6

Mark Clemons

Associate Scientist, Cancer Therapeutics Program
Ottawa Hospital Research Institute
Staff Medical Oncologist, Division of Medical Oncology
The Ottawa Hospital Cancer Centre
Professor, Department of Medicine
University of Ottawa

Research Interests

Dr Mark Clemons is currently a Clinical Investigator at the Ottawa Hospital Research Institute (Cancer Therapeutics Program), staff medical oncologist (Ottawa Hospital Cancer Centre) and Professor of Medicine (University of Ottawa). A proponent of high quality clinical research trial, he is involved in a large number of experimental therapeutic studies for patients with early stage, locally advanced and metastatic breast cancer. He is the recipient of multiple peer-reveiwed research grants and is widely published in the field of breast cancer management. His publications also reflect eclectic topics such as; retirement planning, oncologist quality of life and issues such as preventing spam. His work on strategies to improve tissue acquisition during systemic therapy have also improved the assessment of both the efficacy of novel therapeutic agents but also innovative ways of administering established agents. His current research vision is to remove many of the barriers that lead to the development of multiple standard of care therapies with very little data to actually show which treatment is best in the real world setting

Brief Biography

Dr Mark Clemons graduated from the University of Newcastle upon Tyne, U.K. (B.Med.Sci; MB BS). He completed his post-doctoral training in internal medicine and medical oncology at the Hammersmith Hospital, London; Christie Hospital, Manchester (MSc, Oncology; MD, Oncology) and at the Princess Margaret Hospital, Toronto. He is currently a Clinical Investigator at the Ottawa Hospital Research Institute (Cancer Therapeutics Program), staff medical oncologist (Ottawa Hospital Cancer Centre) and Professor of Medicine (University of Ottawa).

A proponent of high quality clinical trials research, he is involved in a large number of experimental therapeutic studies for patients with early stage, locally advanced and metastatic breast cancer. He is the recipient of multiple peer-reveiwed research grants and is widely published in the field of breast cancer management. His publications also reflect eclectic topics such as; retirement planning, oncologist quality of life and issues such as preventing spam. His work on strategies to improve tissue acquisition during systemic therapy have also improved the assessment of both the efficacy of novel therapeutic agents but also innovative ways of administering established agents. His current research vision is to remove many of the barriers that lead the development of multiple standard of care therapies with very little data to actually show which treatment is best in the real world setting.

Selected Publications

Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G. A Randomized Trial Comparing Risk Model Guided Antiemetic Prophylaxis to Physician's Choice in Patients Receiving Chemotherapy for Early Stage Breast Cancer. JAMA Oncology. Accepted August 7, 2015. – Senior Responsible Author (Impact Factor NA)

Simos D, Catley C, van Walraven C, Arnaout A, Booth CM, McInnes M, Fergusson D, Dent S, Clemons M. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. CMAJ. 2015 Jun 22. pii: cmaj.150003. [Epub ahead of print] PubMed PMID: 26100841. – Senior Responsible Author (Impact Factor 5.9)

Arnaout A, Robertson S, Kuchuk I, Simos D, Pond GR, Addison CL, Namazi M,Clemons M. Evaluating the feasibility of performing window of opportunity trials in breast cancer. Int J Surg Oncol. 2015;2015:785793. doi: 10.1155/2015/785793. Epub 2015 Jan 20. PubMed PMID: 25685551. – Senior Responsible Author. (H index 7)

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat. 2014 Mar 18. [Epub ahead of print] – Senior Responsible Author (Impact Factor 5.881)

Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. A prospective study evaluating the impact of tissue confirmation of metastatic disease in breast cancer patients. Journal of Clinical Oncology 2012;30(6):587-92 – Senior Responsible Author (Impact factor 17.7)